Expert Think Tank: Resources to Improve the Care of Patients With NSCLC and EGFR Mutations

Read this expert commentary to gain insights into the rationale and latest clinical evidence for combination strategies with EGFR TKIs for the first-line treatment of EGFR-mutated advanced NSCLC.

David Planchard, MD, PhD Released: December 3, 2021

What I want my colleagues to know about treating patients with advanced NSCLC and uncommon EGFR mutations, including future directions targeting these mutations.

Joel W. Neal, MD, PhD Released: May 20, 2022

In this commentary, a lung cancer expert highlights advances from ASCO 2022 in the management of EGFR-mutated NSCLC with acquired resistance to first-line EGFR TKI therapy using rational combination regimens composed of third-generation EGFR TKIs, EGFR monoclonal antibodies, bispecific antibodies, and antibody–drug conjugates.

Jonathan Riess, MD, MS Released: July 13, 2022

Adjuvant osimertinib has been approved for the treatment of patients with resectable early-stage EGFR-positive NSCLC for 2 years. A lung cancer expert discusses the continued DFS benefit and lack of OS data to date and reviews considerations for using adjuvant osimertinib in the clinic.

Edward B. Garon, MD, MS Released: October 24, 2022